Janssen Signs Translational Medicine MOU with Shanghai Ruijin Hospital

Janssen Pharma, the pharmaceutical division of Johnson & Johnson, signed a MOU to collaborate on translational research with Shanghai Ruijin Hospital, which opened a Translational Medicine Center in early October. William Hait, global head, R&D at Janssen, told the China Daily that Janssen will provide diagnostic devices and train staff at the hospital. He also said Janssen is looking at several possible acquisitions of innovative China biomedical companies. More details.... Stock Symbol: (NYSE: JNJ) Share this with colleagues: // //